Startseite

Aktien

Agios Pharmaceuticals

Nachrichten

Agios Pharmaceuticals Aktie

Aktie

ISIN: US00847X1046 WKN: A1W2RM SYM: 8AP Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

35,20

EUR

+0,57 %

+0,20 EUR

Letzter Kurs 07.11.25 Tradegate

Agios Pharmaceuticals Aktie kaufen

Geldkurs

07.11.25

35,00

EUR

142 STK

Briefkurs

07.11.25

35,40

EUR

141 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition 03.11.25 · globenewswire · Agios Pharmaceuticals
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update 30.10.25 · globenewswire · Agios Pharmaceuticals
Avanzanite-Bioscience-Partner Agios gibt positive CHMP-Stellungnahme für PYRUKYND (Mitapivat) bei erwachsenen Patienten mit Thalassämie bekannt 17.10.25 · Business Wire (dt.) · Nasdaq Inc. Aktie
Agios’ PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia 17.10.25 · globenewswire · Agios Pharmaceuticals
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8: 00 a.m. ET 16.10.25 · globenewswire · Agios Pharmaceuticals
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO) and Encourages Long-Term Investors to Contact the Firm 24.09.25 · newsfile · Agios Pharmaceuticals
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm 15.09.25 · Business Wire (engl.) · Agios Pharmaceuticals
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia 04.09.25 · globenewswire · Agios Pharmaceuticals
Agios’ PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia 04.08.25 · globenewswire · Agios Pharmaceuticals
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update 31.07.25 · globenewswire · Agios Pharmaceuticals
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8: 00am ET 14.07.25 · globenewswire · Agios Pharmaceuticals
Agios Appoints Dr. Jay Backstrom to Board of Directors 08.07.25 · globenewswire · Agios Pharmaceuticals

1
2
…
3

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and ... 112 Leser

Avanzanite-Bioscience-Partner Agios gibt positive CHMP-Stellungnahme für PYRUKYND (Mitapivat) bei ... 136 Leser
Agios’ PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia 116 Leser
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update 112 Leser
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and ... 112 Leser
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8: 00 a.m. ET 108 Leser

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients ... 264 Leser
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and ... 228 Leser
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio 224 Leser
Agios to Present at Upcoming Investor Conferences 200 Leser
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency ... 184 Leser
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief ... 164 Leser
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ ... 160 Leser
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights 160 Leser
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO) ... 160 Leser
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia 156 Leser